Remdesivir Should Give Gilead’s 2020 Revenue A Needed Lift

 
• By Mandy Jackson

As it prepares to report second quarter earnings that may show coronavirus-related impacts, the company’s antiviral for COVID-19 may boost 2020 revenue and offset need for new products.

Antibodies attacking SARS-CoV-2 virus, the conceptual 3D illustration for COVID-19 treatment, diagnosis and prevention
Gilead's antiviral against the novel coronavirus could give its earnings a blockbuster boost • Source: Shutterstock

More from Earnings

More from Business